Publications:
- Jun 07, 2025 Utilization of a Multi-modal Comprehensive Genomic and Immune Profiling Testing Strategy Results in a High Rate of Test Success and Detection of Clinically Relevant Biomarkers While Optimizing Tissue Usage
- Jan 30, 2025 Fully automated extraction of high-quality total nucleic acids from FFPE specimens for comprehensive genomic profiling of solid tumors
- Nov 23, 2024 Comprehensive genomic and immune profiling for the detection of clinically significant tumor biomarkers
- Nov 23, 2024 Analytical validation of OmniSeq® INSIGHT whole transcriptome sequencing assay to facilitate precision oncology through tumoronly testing in solid tumors
- Nov 23, 2024 Analytical validation of OmniSeq® INSIGHT whole exome sequencing assay to facilitate precision oncology through tumor only testing in solid tumors
- Nov 23, 2024 Validation of automated nucleic acid extraction using Covaris® Gen3 extraction methodology on the Assay-Ready Workstation
- Oct 30, 2024 Case report: Single gene testing and comprehensive genomic profiling in non-small cell lung cancer - a case series of divergent results from a large reference laboratory
- Oct 29, 2024 A consensus-based classification workflow to determine genetically inferred ancestry from comprehensive genomic profiling of patients with solid tumors
- May 01, 2024 OX40/OX40 Ligand and its Role in Precision Immune Oncology
- Apr 29, 2024 Immunologic factors associated with differential response to neoadjuvant chemoimmunotherapy in triple negative breast cancer
- Apr 07, 2024 Landscape of HIF-1-alpha expression across 24,186 solid tumors using comprehensive immune profiling
- Apr 07, 2024 Landscape of TIGIT and PD-L1 co-expression in solid tumors
- Mar 19, 2024 The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer
- Feb 12, 2024 Comprehensive Genomic Testing: Tissue Stewardship and Best Practices
- Feb 05, 2024 Fully Automated Extraction of High-Quality Total Nucleic Acids from FFPE Specimens using Covaris truXTRAC® FFPE SMART Solutions & Hamilton Robotics
- Feb 05, 2024 Implementation of Laboratory Automation to Support Scaling of Cancer Patients Testing using OmniSeq® INSIGHT Molecular Diagnostic Test
- Feb 04, 2024 Automated Tissue Dissection Solution to Support Comprehensive Genomic and Immune Profiling
- Jan 30, 2024 LAG-3 transcriptomic expression correlates linearly with other checkpoints, but not with clinical outcomes
- Jan 13, 2024 Pan‐cancer analysis of TIM‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity
- Dec 11, 2023 Findings of clinically significant variants (Tier IA) with comprehensive genomic profiling in a breast cancer patient cohort
- Dec 11, 2023 Comprehensive immune profiling reveals factors associated with neoadjuvant chemotherapy response in triple negative breast cancer
- Nov 17, 2023 Non-V600 BRAF mutated melanomas have immune microenvironments primed for immune checkpoint inhibitor response
- Nov 17, 2023 Genomic stability of prostate cancers with homologous recombination gene alterations
- Nov 17, 2023 Genomic landscape of ERBB2 alterations in solid tumors without an approved HER2-targeted therapy
- Nov 17, 2023 Validation of a tumor-informed HLA typing assay to support drug development and clinical decision making
- Nov 17, 2023 LAG-3 expression by RNA next-generation sequencing: Comparison with LAG-3 immunohistochemistry in melanoma
- Nov 17, 2023 A Consensus-Based Machine Learning Framework to Determine Genetically Inferred Ancestry (GIA) from Comprehensive Genomic Profiling (CGP) Sequencing Results
- Nov 04, 2023 Distinct immunotherapy immune response phenotypes in non-small cell lung cancer present with unique genomic alteration profiles
- Nov 03, 2023 Molecular and immune profiling of lobular-enriched versus non-lobular invasive breast cancers
- Nov 03, 2023 Characterization of gene expression signatures of tumor immunogenicity and cellular proliferation from murine cancer models grown in vitro and in vivo
- Nov 03, 2023 Comprehensive genomic and immune profiling of ALK fusion-positive and negative lung adenocarcinomas
- Nov 03, 2023 Comprehensive genomic and immune profiling (CGIP) reveals a distinct genomic and immune gene expression profile for younger patients with non-small cell lung cancer (NSCLC)
- Nov 03, 2023 Immune microenvironment of primary versus metastatic melanoma of the brain
- Nov 03, 2023 Metastatic triple negative breast cancer has distinct tumor immune landscape
- Nov 01, 2023 Comprehensive Genomic and Immune Profiling of Early-Onset Colorectal Cancer
- Sep 29, 2023 PD-L1 Expression by RNA-Sequencing in Non-Small Cell Lung Cancer: Concordance with Immunohistochemistry and Associations with Pembrolizumab Treatment Outcomes
- Aug 08, 2023 T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy
- Jun 13, 2023 LAG-3 transcriptomic expression patterns across malignancies: Implications for precision immunotherapeutics
- Jun 06, 2023 Sex-specific effects of body composition on tumor microenvironment in non–small cell lung cancer
- Jun 06, 2023 The impact of single gene testing (SGT) on subsequent comprehensive genomic profiling (CGP) success in community oncology practice for advanced non-small cell lung cancer (NSCLC)
- May 26, 2023 Association of antifolate response signature status and clinical activity of pemetrexed platinum chemotherapy in non-small cell lung cancer - The Piedmont Study
- May 08, 2023 RNA sequencing identifies novel NRG1 fusions in solid tumors that lack co-occurring oncogenic drivers
- Sep 12, 2022 Cancer testis antigen burden: pan-cancer distribution and survival implications
- Sep 02, 2022 Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
- Mar 02, 2022 Checkpoint coexpression landscape in gastroesophageal adenocarcinoma
- Jan 02, 2018 Analytical validation of a next-generation sequencing assay to monitor immune responses in solid tumors
- Feb 14, 2024 Cancer testis antigen burden (CTAB): a novel biomarker of tumor‑associated antigens in lung cancer
